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Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used in avian medicine for 38 
their antipyretic, analgesic and anti-inflammatory properties both during surgery and diseases 39 
related with tissue damage and/or inflammation. NSAIDs inhibit cyclooxygenase (COX) 40 
enzymes, which are responsible for the induction of pyresis, pain and inflammation. In the 41 
current study, an Lipopolysaccharide-induced (LPS) pyresis model was optimized and 42 
validated in cockatiels (Nymphicus hollandicus). An intravenous bolus injection of LPS (7.5 43 
mg/KG BW) was administered at T0 and T24 (24 hour following the first LPS injection), 44 
followed by the assessment of the pharmacodynamic (PD) parameters of the NSAIDs 45 
mavacoxib (4 mg/kg BW), celecoxib (10 mg/kg BW) and meloxicam (1 mg/kg BW). The PD 46 
parameters (body temperature, clinical appearances, preference of location in the cage and 47 
prostaglandin E2 (PGE2) plasma concentrations) were determined during 10 hours following 48 
the second LPS injection. Both mavacoxib and celecoxib were able to reduce the LPS-49 
induced hypothermia, but only mavacoxib had a significant increase in clinical appearance of 50 
the birds. In contrast, no influence on hypothermia and clinical appearance was observed in 51 
the LPS-challenged cockatiels treated with meloxicam. The three NSAIDs were able to inhibit 52 
the increase in LPS-induced PGE2 plasma concentrations, however the effect was most 53 
pronounced in the birds treated with meloxicam. Based on the presented results, both 54 
celecoxib and mavacoxib are more effective than meloxicam to treat hypothermia. Mavacoxib 55 












Keywords  66 
lipopolysaccharide, pharmacodynamic, mavacoxib, celecoxib, meloxicam, cockatiel 67 
 68 
List of abbreviations 69 
AUC Area under the plasma concentration-time curve 
ABV Avian Bornavirus 
BW Body weight 
COX Cyclooxygenase 
IV Intravenous  
LPS Lipopolysaccharide 
NSAID Non-steroidal anti-inflammatory drugs 
PDD Proventricular dilatation disease 
PD Pharmacodynamic 
PK Pharmacokinetic 
PGE2 Prostaglandin E2 
Tx Time before/after administration 
UPLC-MS/MS Ultra-performance liquid chromatography - tandem mass spectrometry 
  70 
4 
 
1. INTRODUCTION 71 
Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used in avian clinical 72 
practice for their anti-inflammatory, antipyretic and analgesic properties. Although research 73 
determining the efficacy of analgesics in avian patients is still in its infancy, the usefulness of 74 
NSAIDs has already been proven during clinical trials1. NSAIDs reversibly inhibit the 75 
cyclooxygenase (COX) enzyme activity, which catalyzes the formation of prostanoids, such 76 
as prostaglandins, prostacyclins and thromboxanes, from arachidonic acid2,3,4. Three related 77 
COX enzyme isoforms have been distinguished, COX-1, COX-2 and COX-3. COX-1 is 78 
constitutively expressed in most tissues and is related to gastric cytoprotection, regulation of 79 
homeostasis, renal blood flow maintenance and platelet aggregation3,4,5. COX-2, which is 80 
expressed less constitutively than COX-1, is primarily induced in response to inflammatory 81 
stimuli, such as lipopolysaccharide (LPS), cytokines and injury. COX-2 causes vasodilation, 82 
increasing vascular permeability, chemotaxis, hyperalgesia and potentiation of other 83 
inflammation mediators (i.e. histamine)3,6,7,8.  84 
Meloxicam is an enolcarboxamide indicated in avian species for the treatment of various 85 
painful and/or inflammatory conditions (i.e. proventricular dilatation disease (PDD)) as well 86 
as the treatment of birds suffering from inflammation caused by chronic locomotive diseases2. 87 
Meloxicam is a preferential COX-2 enzyme inhibitor at low therapeutic doses, but higher 88 
doses might also induce inhibition of COX-1 enzyme activity (i.e. in human ratio of 50% 89 
inhibitory concentration for COX-2/COX-1 = 0.09 in whole blood assays), potentially causing 90 
side-effects such as gastrointestinal toxicity, cardiovascular side-effects, etc.2,9,10. The coxibs, 91 
such as celecoxib and mavacoxib, are selective COX-2 enzyme inhibitors, which provide 92 
inhibition of COX-2 enzyme activity without altering the COX-1 enzyme activity. In birds, 93 
celecoxib is frequently prescribed by veterinarians to symptomatically treat PDD. PDD is a 94 
progressive avian disease affecting Psittaciformes which is caused by an avian Bornavirus 95 
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(ABV)-induced inflammatory response of the gastrointestinal tract as well as the central and 96 
peripheral nervous system11,12. Mavacoxib is considered as one of the standard therapies to 97 
treat dogs suffering from osteoarthritis, but its use in avian clinical practice is until now not 98 
common13,14. To date, only limited studies have been published investigating the anti-99 
inflammatory, antipyretic and analgesic properties of selective COX-2 enzyme inhibitors in 100 
birds15,16,17. In 2013, Hoppes et al.16 investigated the efficacy of meloxicam on disease 101 
development and mortality in ABV-infected cockatiels (Nymphicus hollandicus). The authors 102 
demonstrated that the use of meloxicam might enhance the severity of the ABV infection due 103 
to changes in gastrointestinal physiology. Recently, Dhondt et al.17 determined the 104 
pharmacokinetics (PK) and absolute oral bioavailability of celecoxib, mavacoxib and 105 
meloxicam in cockatiels. Mavacoxib had a prolonged elimination half-life, enabling less 106 
frequent dosing compared to celecoxib and meloxicam. Both authors16,17 concluded that 107 
additional pharmacodynamic (PD) and safety studies are necessary to further conclude if 108 
NSAIDs are useful in the treatment of PDD and other painful/inflammatory conditions. 109 
LPS (endotoxin) can be found in the outer membrane of Gram-negative bacteria and provokes 110 
immune responses resulting in i.e. a change in body temperature, increase in cytokine 111 
production and sickness18. In 2001, Escherichia coli LPS models have been accepted by the 112 
European Medicine Agency for the evaluation of anti-inflammatory, antipyretic and analgesic 113 
properties of different NSAIDs19. LPS models have already been developed and validated in 114 
both mammals20,21 and broiler chickens22, but to the author’s knowledge a cockatiel LPS-115 
induced model still needs to be developed.  116 
The aim of the present study was to evaluate the antipyretic and anti-inflammatory properties 117 
of NSAIDs in cockatiels (Nymphicus hollandicus), as model for the Psittaciformes. An in vivo 118 
cockatiel LPS model was developed and validated to study the PD parameters (body 119 
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temperature, clinical appearance and plasma prostaglandin E2 (PGE2) concentration) of the 120 
COX-2 inhibitors celecoxib, mavacoxib and meloxicam.  121 
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2. MATERIALS AND METHODS 122 
2.1 Animals 123 
This study was conducted with consent of the ethical committee of the Faculty of Veterinary 124 
Medicine and Bioscience Engineering of Ghent University (EC2015/114). Care and use of 125 
animals was in full compliance with the most recent national legislation23 and European 126 
Directive24. A group of 45 cockatiels (Nymphicus hollandicus) (23♂/22♀, 102 ± 12 g, 6-12 127 
months old) were group-housed in an aviary (16 m³) during a two-week acclimatization 128 
period at the start of the study and during the recovery period after the trial. Birds were cage-129 
housed in pairs, 12h prior the start of the experiment until 12h after the end of the experiment. 130 
Animals had ad libitum access to a commercially available seed mixture (Big Parakeets 131 
Prestige, Versele-Laga, Deinze, Belgium) and tap water. The mean room temperature during 132 
acclimatization and experiments was 20 ± 3°C and a 12h light/ 12h dark cycle was applied 133 
(light provided by artificial lights).  134 
 135 
2.2  Development and validation intravenous LPS model 136 
2.2.1 LPS dose determination study 137 
Seven cockatiels (4♂/3♀) were included to determine the correct dosing protocol for the LPS 138 
model. One day prior to the experiments, a temperature sensing pet microchip (Temperature 139 
sensing radio-frequency identification base plate system, Biomark Inc., Idaho, USA) was placed 140 
subcutaneously in the left pectoral muscle region of the cockatiels. Immediately prior to 141 
administration, LPS was mixed with physiological saline (5 mg LPS/mL, 0.9% NaCl). At T0 142 
(time of administration), an intravenous (IV) single bolus of LPS (Escherichia coli 0127:B8 143 
purified by phenol extraction, ≥ 500,000 EU/mg, Sigma-Aldrich, Bornem, Belgium) was 144 
administered in the vena cutanea ulnaris superfacialis (wing vein) to five birds. Each bird 145 
received a different dosage: 2.5, 5, 7.5, 10 and 25 mg/kg body weight (BW), respectively. 146 
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Body temperate of the birds was registered before and every 30 minutes after administration 147 
using a microchip reader (Biomark BIO310/303TS-ANT reader platform, Biomark Inc.). An 148 
IV dose of 7.5 mg/kg was considered optimal to induce a clear difference in body temperature 149 
(hypothermia) without mortality. Since the body temperature of the cockatiels fluctuated 150 
strongly after a single LPS administration, the impact of the source of LPS and a second LPS 151 
injection (24 hours after the first injection) on the body temperature was evaluated. Therefore, 152 
two cockatiels received either a double IV bolus of LPS from E. coli or a double IV bolus of 153 
LPS from Salmonella Enteritidis purified by phenol extraction (≥ 500,000 EU/mg, Sigma-154 
Aldrich), at a dosage of 7.5 mg/kg BW per bolus. No impact of the source of LPS was 155 
observed. Fluctuation of body temperature was less when administering a second LPS 156 
injection and the hypothermia was more pronounced (data not shown). 157 
 158 
2.2.2 Model validation study 159 
Six cockatiels were randomly divided into two groups (LPS or negative control) of three birds 160 
(2♂/1♀). At T0 and T24 (24 hours after the first LPS administration), a 7.5 mg/kg BW IV LPS 161 
bolus (E. coli 0127:B8 purified by phenol extraction, ≥ 500,000 EU/mg, Sigma-Aldrich) or an 162 
equivalent 0.9% NaCl bolus was administered to LPS or negative control group, respectively. 163 
Body temperature was monitored after the second LPS administration as described in section 164 
2.2.1 to validate the model.  165 
 166 
2.3 Pharmacodynamic study 167 
2.3.1 Products 168 
The LPS solution was prepared as described in section 2.2.1. Commercially available tablets 169 
of celecoxib (Celebrex 100 mg®, Pfizer, Brussel, Belgium) and mavacoxib (Troxocil 20 170 
mg®, Zoetis, Zaventem, Belgium) were grinded and lactose was added until a concentration 171 
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of 10 mg/g and 4 mg/g was obtained, respectively. Prior to oral administration, the mixture 172 
was dissolved in 0.9% NaCl to obtain a solution of 5 mg celecoxib/mL and 2 mg 173 
mavacoxib/mL. A commercially available 0.5 mg/mL meloxicam suspension (Metacam 0.5 174 
mg/mL®, Boehringer Ingelheim Vetmedica, Ingelheim/Rhein, Germany) was used. 175 
 176 
2.3.2 Experimental design  177 
Thirty-two cockatiels were included in the PD study and were randomly divided into four 178 
groups of eight animals (4♂/4♀). All birds received an IV LPS bolus injection (7.5 mg/kg, E. 179 
coli 0127:B8 purified by phenol extraction, ≥ 500,000 EU/mg, Sigma-Aldrich) at T0 and T24. 180 
At T12 and T22 (12 hours and 22 hours after the first LPS administration, respectively), the 181 
birds received a 2 mL intra-crop feed bolus (Nutribird A19 High Energy (Versele-Laga):tap 182 
water, 25:75, v-v) administered with a curved stainless steel ball tipped feeding needle (ø 183 
2.50mm). The negative control group did not receive any treatment. To administer the second 184 
LPS injection concurrently at the moment of the maximum plasma concentration of the 185 
different NSAIDs, mavacoxib (4 mg/kg BW), celecoxib (10 mg/kg BW) and meloxicam (1 186 
mg/kg BW) were administered orally (intra-crop bolus) at corresponding time points (T12, T22, 187 
T23) to the birds of the mavacoxib, celecoxib and meloxicam group, respectively (Figure 1)17. 188 
Body temperature was assessed after the second LPS administration as described in section 189 
2.1.1. Besides, the health and position of the birds were recorded from T24 until T34 using 190 
camera-assisted recording. Different clinical parameters were assessed, including state of 191 
consciousness (alertness, apathetic, soporose) signs of illness (ruffled feathers and dyspnea), 192 
and time spent on feed- and water uptake, grooming behavior, and exercise (climbing or 193 
flying). The percentage of time the bird showed a certain state of consciousness, signs of 194 
illness, and time spent on a certain activity was calculated based on a snapshot monitoring 195 
method with an interval of 5 min. Moreover, the location of the bird in the cage (on the wire 196 
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mesh, on one of both perches or on the floor) was monitored and the percentage of time spent 197 
on a certain location was calculated. 198 
 199 
2.3.3 Plasma sampling  200 
A sparse sampling protocol was applied because of the limited volume of blood that can be 201 
drawn from the cockatiels. Therefore, all sampling points were randomly allocated to 202 
different birds within one group, with three sampling points per bird. Blood (0.3 mL/ time 203 
point) was sampled by venipuncture from the jugular vein (vena jugularis) with a 1 mL 204 
syringe and 29G needle. Blood samples were collected at T0 (just before administration) and 205 
T24, T24.5, T25, T26, T28 and T30 post administration. The samples were transferred into 206 
heparinized collection Eppendorf tubes coated with 10 µg/mL indomethacin (Sigma Aldrich, 207 
Diegem, Belgium) and 10 IU heparin (Leo Pharma, Lier, Belgium). Samples were 208 
immediately placed on ice and centrifuged for 10 min at 2851 g (4°C) within 2h after blood 209 
collection. Supernatant was aliquoted, frozen and stored at -70°C until PE2 plasma 210 
concentration analysis. 211 
 212 
2.3.4 Prostaglandin E2 plasma concentration determination  213 
PGE2 plasma concentrations were determined by UPLC-MS/MS (ultra-performance liquid 214 
chromatography - tandem mass spectrometry) analysis that was based on Plessers et al.25. The 215 
prostaglandins were extracted using a liquid-liquid extraction. In brief, to 50 µl of plasma 216 
were added 25 µL of the internal standard working solution (10 ng/mL, PGE2-d4) and 200 µL 217 
of water. The sample was vortexed (15 sec) and acidified using 25 µl of a 1N hydrogen 218 
chloride solution. After vortex mixing (15 sec) 6 mL of the extraction solvent (hexane/ethyl 219 
acetate, 1/1, v/v) were added. Samples were extracted for 25 min on a roller mixer (Stuart 220 
Scientific, Surrey, UK) and centrifuged (2851 × g, 10 min, 4°C). Next, the supernatant was 221 
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transferred to a glass tube and evaporated using a gentle nitrogen (N2) stream (40 ± 5°C). The 222 
dry residue was reconstituted in 125 μL of a methanol/water (1/9, v/v) mixture. After vortex 223 
mixing (15 sec), the samples were filtered through a Millex® PVDF syringe filter (0.22 µm) 224 
and transferred into an autosampler vial. An aliquot (10 μL) was injected onto the UPLC-225 
MS/MS instrument for quantification of the PGE2 concentration.  226 
For each group, the mean area under the plasma concentration-time curve (AUC) was 227 
calculated using Graphpad 5 Software (Prism, La Jolla, CA, USA).  228 
 229 
2.4 Statistical analysis  230 
The AUC and individual body temperatures were compared between the different treatment 231 
groups and the control group using one way-analysis of variance (ANOVA, SPSS 23.0, IBM 232 
Corporations, New York, USA). Post-hoc comparisons were performed according to the 233 
Dunnett t-test. The level of significance was set at 0.05. A sinus transformation of the 234 
percentage of time the birds exhibit the above described behavioral changes and the time 235 
spent on a certain location was first performed before conducting the statistical analysis. One-236 
way ANOVA analysis was performed to compare the percentage the cockatiels of the 237 
different groups showed a certain state of consciousness, signs of illness, time spent on feed- 238 
and water uptake, grooming behavior, exercise, and time spent on a certain location during 239 
hypothermia (T24-28), the period after hypothermia (T28-34) and the entire experiment (T24-34). 240 
Post-hoc comparisons between the treatment and control groups were performed according to 241 
the Dunnett t-test. The level of significance was set at 0.05. The sparse sampling procedure 242 
applied, made it not possible to perform any statistical analysis on the difference of AUC of 243 
PGE2 of the different treatment groups.  244 
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3.  RESULTS 245 
3.1  LPS model validation study 246 
Mean (±SD) body temperatures of both groups during the model validation study (LPS group 247 
and negative control group) are depicted in Figure 2. In the LPS group, hypothermia was 248 
observed at T24-28, with the lowest body temperature measured at T25.5 (39.9 ± 1.15°C), 249 
followed by a plateau phase corresponding with the normal body temperature of the cockatiels 250 
(41.4 ± 0.69°C). An increase in body temperature (41°C to 42°C) was observed at T32-34 due 251 
to elimination of LPS, leading to an increase in activity of the birds. In the negative control 252 
group, no hypothermia was observed. The mean body temperature in the negative control 253 
group was higher at T24-28 (41.6 ± 0.56°C) than at T28-34 (41.2 ± 0.72°C) since the birds got 254 
used to the manipulations and the presence of humans in the room. 255 
 256 
3.2 Pharmacodynamic study 257 
One bird was excluded from the control group, due to prolonged hypothermia and severe 258 
clinical signs of illness. One bird was excluded from the mavacoxib group due to 259 
regurgitation of the drug, leading to underdosing of mavacoxib. One bird of the meloxicam 260 
and celecoxib group died immediately after the second LPS administration (T24). All other 261 
birds were adopted after the experiments.  262 
 263 
3.2.1 Body temperature 264 
The mean body temperature of the four different groups (control, mavacoxib, celecoxib and 265 
meloxicam) is depicted in Figure 3. The mean body temperature of the control group 266 
demonstrated hypothermia during the first 4h following the second LPS injection. In the 267 
control group, the lowest body temperature was observed at T25.5 (40.2 ± 0.89°C). After 268 
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hypothermia, the mean body temperature raised (T26-27.5) and fluctuated around 41.4 ± 0.88°C 269 
until the end of the experiment (T28-34). The evolution of the mean body temperature of the 270 
cockatiels treated with meloxicam was comparable to the control group. However, 271 
hypothermia was less pronounced (lowest body temperature (T26): 40.6 ± 0.47°C). A mild 272 
hypothermia was observed in the birds treated with mavacoxib and celecoxib with the lowest 273 
temperature observed at T25.5 (41.5 ± 0.51°C) and T26 (41.3 ± 0.74°C), respectively.  274 
No significant difference in AUC was observed between the different groups for the period 275 
during hypothermia (T24-28, p = 0.76) and the period after hypothermia (T28-34, p = 0.28). 276 
When comparing the individual time points during hypothermia, a significant difference 277 
between the different groups could only be observed at T25, T25.5, T26 and T26.5. No significant 278 
difference in mean body temperature could be observed during hypothermia (T24-28) between 279 
the control group and the cockatiels treated with meloxicam (p = 0.22-0.99). The mean body 280 
temperature of the birds treated with mavacoxib was significantly different from the control 281 
group at T25, T25.5 and T26 (p < 0.01). A significantly higher mean body temperature was 282 
observed in the group treated with celecoxib in comparison with the control group at T25 (p = 283 
0.03) and T25.5 (p = 0.01). 284 
 285 
3.2.2 State of consciousness and signs of illness 286 
A significant decrease in alertness, and increase in dyspnea and ruffled feathers was observed 287 
in all groups during hypothermia (T24-28) in comparison with the period after hyperthermia 288 
(T28-34)(p < 0.01) (Table 1). No significant differences were observed between the cockatiels 289 
treated with one of the three NSAIDs (mavacoxib (p = 0.22), celecoxib (p = 0.47), meloxicam 290 
(p = 0.88)) and the control group in the percentage of time showing alertness, dyspnea and 291 
ruffled feathers during the entire experiment (T24-34). Only the cockatiels treated with 292 
mavacoxib were significantly more alert during hypothermia (p = 0.04) and showed less 293 
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ruffled feathers during the period after hypothermia (p = 0.02) in comparison with the control 294 
group. 295 
 296 
Little activity (less than 50% of the time) was observed during the entire experiment in all 297 
groups (Table 2). No significant differences in activity (p = 0.18) and grooming (p = 0.29) 298 
was observed between the different groups. In general, the time spent with feed- and water 299 
uptake was low during the trial.  300 
 301 
The preferential location in the cage of the cockatiels after the second LPS injection was on 302 
the floor and on the perch (Table 3). No significant differences in percentage of time spend 303 
on the floor, wire mesh or perch was observed between the different treatment groups 304 
compared to the control group (p = 0.93, p = 0.67 and p = 0.95, respectively). 305 
 306 
3.2.3 Plasma prostaglandin E2 concentration 307 
The mean plasma PGE2 concentration (+SD) of the control and NSAID treated groups are 308 
depicted in Figure 4. The mean plasma PGE2 concentration of the control group described a 309 
maximum at T24.5, followed by a plateau phase and a steady decrease after T28. The average 310 
AUC of the control group (1038.0 h.pg/mL) was higher in comparison with the birds treated 311 
with mavacoxib (628.3 h.pg/mL), celecoxib (526.3 h.pg/mL) and meloxicam (222.0 312 
h.pg/mL), respectively.   313 
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4. DISCUSSION 314 
For the first time an in vivo cockatiel LPS-induced inflammation model was developed to 315 
study the PD parameters (body temperature, clinical appearance and plasma PGE2 316 
concentration) of the selective COX-2 inhibitors celecoxib, mavacoxib and meloxicam. In the 317 
present study, hypothermia was observed after IV LPS administration to cockatiels 318 
(Psittaciformes). This was in accordance with the LPS-induced body temperature changes 319 
detected by Burness et al.26 in Passeriformes (Zebra finches, Taeniopygia guttata). These 320 
observations were in contrast with the results obtained in chickens and pigeons, where a short 321 
period of hypothermia was followed by hyperthermia. In ducks and Japanese quails, only 322 
hyperthermia occurred after IV LPS administration27. In accordance with the Passeriformes, 323 
the observed hypothermia might be linked with the high body surface area-volume ratio in 324 
association with the high body temperature of cockatiels. Consequently, relative heat loss is 325 
higher in cockatiels in comparison to larger birds species, which complicates 326 
thermoregulation. Moreover, small birds, such as cockatiels, are characterized by a higher 327 
basal metabolic rate compared to larger bird species. The mean body temperature of 328 
cockatiels is already high (41.7°C), whereby an increase in body temperature is complicated, 329 
since an increase in body temperature of 1°C requires an increase of 10% in metabolism28,29. 330 
 331 
During the period after hypothermia, body temperature fluctuated around 41.4 °C, probably 332 
due to an increase in alertness and activity (flying and climbing) of the birds, leading to a 333 
stress-induced increase in body temperature during measurements. The decrease in time spent 334 
on grooming behavior, and feed- and water consumption was probably due to stress caused by 335 
the frequent handlings performed during the experiments.  336 
The changes in body temperature and clinical appearance are more pronounced when 337 
administering mavacoxib in comparison to the other NSAIDs tested in the current study. This 338 
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might be associated with the higher oral bioavailability of mavacoxib compared to the other 339 
NSAIDs (mavacoxib: 111-113%, celecoxib: 56-110%, meloxicam: 11%)14,17. Besides, the 340 
clearance of mavacoxib is slower (mavacoxib: 0.033 L/h.kg, celecoxib: 4.32 L/h.kg, 341 
meloxicam: 3.38 L/h.kg), leading to a longer elimination half-life (mavacoxib: 135.41 h, 342 
celecoxib: 0.88 h, meloxicam: 0.90 h) and a prolonged therapeutic effect17. Finally, tissue 343 
distribution of mavacoxib is higher due to its larger volume of distribution (mavacoxib: 6.35 344 
L/kg, celecoxib: 5.49 L/kg, meloxicam: 4.40 L/kg), possibly influencing the local 345 
prostaglandin production17,30.  346 
 347 
The extent of inhibition of the COX-2 enzyme activity was determined by measuring the 348 
PGE2 plasma concentration. The lowest and highest PGE2 plasma concentrations were 349 
achieved after administration of meloxicam and mavacoxib, respectively. These results are in 350 
contrast with the other observed PD effects, where the effects on body temperature and 351 
clinical appearance of mavacoxib were more pronounced than meloxicam. PGE2 production is 352 
both expressed constitutively as induced by inflammation31,32. Meloxicam has an influence on 353 
both mechanisms, possibly leading to lower PGE2 plasma concentrations. Whereas 354 
mavacoxib and celecoxib are COX-2 selective inhibitors and have only an influence on PGE2 355 
production induced by inflammation. The lack of correlation between changes in body 356 
temperature and plasma PGE2 concentration, was in contrast with the results obtained in 357 
mammals, but was similar with the results observed in broiler chickens20,21,22. A first 358 
explanation might be that in birds other prostaglandin systems might be involved in LPS-359 
induced temperature and behavioral changes. Whether the changes in body temperature are 360 
caused by peripheral or central production of prostaglandins remains unknown. A second 361 
explanation might be the high lipophilicity of mavacoxib and celecoxib, enabling better 362 
penetration of the central nervous system, influencing thermoregulation33. This theory was 363 
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also opted by Johnson et al.34, who administrated indomethacin centrally and was able to 364 
inhibit the LPS-induced hyperthermia. Moreover, Guo et al.35 administered celecoxib to rats 365 
and discovered an inhibition of the central COX-2 expression. Consequently, the changes in 366 
body temperature and behavior might be explained by the inhibition of the production of 367 
cerebral prostaglandins. 368 
 369 
5. CONCLUSIONS 370 
In conclusion, an in vivo cockatiel LPS-induced inflammation model to study the PD of the 371 
COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam was developed. The present 372 
study demonstrated that the birds treated with mavacoxib and celecoxib are less prone to LPS-373 
induced hypothermia in comparison to meloxicam. Despite the lack of a clear correlation 374 
between illness and changes in body temperature, an increased alertness was observed after 375 
administration of mavacoxib. Consequently, suggesting that mavacoxib was more effective 376 
for the treatment of LPS-induced hypothermia than meloxicam and celecoxib. The absence of 377 
a correlation between the change in body temperature and plasma PGE2 concentration 378 
demonstrated that different mechanisms might be involved in thermoregulations. Further 379 
research is required to determine the specific role of the prostaglandins in hypothermia 380 
(central or peripheral PGE2 production) in birds.  381 
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Table 1. Mean percentage (± SD) of time the cockatiels (n = 7, for each group) showed a 494 
certain state of consciousness and signs of illness after a second LPS injection combined with 495 
no (control), mavacoxib, celecoxib and meloxicam treatment. 496 
Period during hypothermia (T24-28) 
Control Mavacoxib Celecoxib Meloxicam
alertness (%) 22.2 ± 5.9 54.0 ± 11.2* 36.5 ± 10.2 23.8 ± 5.6 
apathetic (%) 17.5 ± 5.9 11.1 ± 5.4 27.0 ± 4.8 20.6 ± 6.1 
soporose (%) 60.3 ± 10.0 34.9 ± 10.1 36.5 ± 11.8 55.6 ± 10.6 
ruffled feathers 
(%) 38.1 ± 10.0 66.7 ± 10.8 57.1 ± 15.0 41.3 ± 10.2 
dyspnea (%) 14.3 ± 9.9 20.6 ± 10.7 1.6 ± 1.6 9.5 ± 9.5 
Period after hypothermia (T28-34) 
Control Mavacoxib Celecoxib Meloxicam
alertness (%) 60.7 ± 15.8 73.8 ± 17.0 63.1 ± 13.1 51.2 ± 14.5 
apathetic (%) 13.1 ± 6.5 1.2 ± 1.2 20.2 ± 7.0 20.2 ± 8.7 
soporose (%) 26.2 ± 16.9 25.0 ± 16.2 16.7 ± 13.1 28.6 ± 12.2 
ruffled feathers 
(%) 11.9 ± 3.1 60.7 ± 16.7* 47.6 ± 15.9 11.9 ± 3.6 
dyspnea (%) 0.0 ± 0.0 4.8 ± 4.8 0.0 ± 0.0 2.4 ± 2.4 
Entire experiment (T24-34)  
Control Mavacoxib Celecoxib Meloxicam
alertness (%) 41.4 ± 10.7 63.6 ± 13.0 45.7 ± 8.0 36.4 ± 8.3 
apathetic (%) 15.7 ± 4.3 5.7 ± 2.3 24.3 ± 4.7 21.4 ± 6.8 
soporose (%) 42.9 ± 13.3 30.7 ± 13.2 30.0 ± 9.5 41.4 ± 8.0 
ruffled feathers 
(%) 73.6 ± 12.9 50.7 ± 14.5 50.7 ± 15.8 79.3 ± 5.9 
dyspnea (%) 7.9 ± 4.3 12.1 ± 7.1 0.7 ± 0.7 5.7 ± 5.7 
*results are significantly different from the control group (p < 0.05) 
  497 
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Table 2. Mean (±SD) percentage of time the cockatiels (n = 7, for each group) were active 498 
(climbing or flying), grooming and consume feed-and water after a second LPS injection 499 
combined with no (control), mavacoxib, celecoxib and meloxicam treatment. 500 
 Control Mavacoxib Celecoxib Meloxicam 
activity (%) 33.8 ± 5.0 33.3 ± 4.4 44.2 ± 5.1 44.0 ± 3.5 
grooming (%) 0.3 ± 0.2 3.9 ± 1.9 0.9 ± 0.7 2.1 ± 1.9 
feed- and water consumption (%) 0.8 ± 0.4 0.0 ± 0.0 1.7 ± 0.4 0.7 ± 0.5 
  501 
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Table 3. Mean (±SD) percentage of time the cockatiels (n = 7, for each group) spent on a 502 
certain location in the cage after a second LPS injection combined with no (control), 503 
mavacoxib, celecoxib and meloxicam treatment. 504 
Control Mavacoxib Celecoxib Meloxicam Mean 
floor (%) 45.8 ± 13.5 33.8 ± 9.6 36.0 ± 13.4 37.7 ± 11.3 38.3 ± 11.5 
wire mesh (%) 16.1 ± 5.7 24.7 ± 6.8 21.3 ± 12.4 13.8 ± 5.8 19.0 ± 7.9 
perch (%) 38.0 ± 13.2 41.4 ± 12.6 42.7 ± 12.2 48.5 ± 8.9 42.7 ± 11.3 
  505 
25 
 
Figure 1. Experimental design pharmacodynamic study. LPS1/2: lipopolysaccharide dose 1 506 
and 2, respectively; T: time point post first LPS administration (h). 507 
 508 
Figure 2. Evolution of mean (±SD) body temperature after second LPS (7.5 mg/kg BW) 509 
(LPS, □) and an equivalent 0.9% NaCl bolus (control, Δ) administration in cockatiels (n = 3 510 
for each group). 511 
 512 
Figure 3. Evolution of mean (+SD last time point) body temperature of cockatiels (n = 7, for 513 
each group) after receiving a second LPS injection combined with no (control), mavacoxib, 514 
celecoxib and meloxicam treatment. 515 
 516 
Figure 4. Mean (+SD) plasma prostaglandin E2 concentration versus time curves of 517 
cockatiels (n = 7, for each group) after receiving a second LPS injection combined with no 518 
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